Fujian Wanchen Biotechnology Group Balance Sheet Health
Financial Health criteria checks 5/6
Fujian Wanchen Biotechnology Group has a total shareholder equity of CN¥1.2B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 105.2%. Its total assets and total liabilities are CN¥6.5B and CN¥5.3B respectively. Fujian Wanchen Biotechnology Group's EBIT is CN¥648.2M making its interest coverage ratio 15.7. It has cash and short-term investments of CN¥2.3B.
Key information
105.2%
Debt to equity ratio
CN¥1.25b
Debt
| Interest coverage ratio | 15.7x |
| Cash | CN¥2.29b |
| Equity | CN¥1.19b |
| Total liabilities | CN¥5.27b |
| Total assets | CN¥6.46b |
Recent financial health updates
Recent updates
Fujian Wanchen Biotechnology Group's (SZSE:300972) Strong Earnings Are Of Good Quality
Nov 04
Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company
Oct 01Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing
Sep 30We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt
Aug 04Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)
Jun 06Financial Position Analysis
Short Term Liabilities: 300972's short term assets (CN¥4.9B) exceed its short term liabilities (CN¥4.6B).
Long Term Liabilities: 300972's short term assets (CN¥4.9B) exceed its long term liabilities (CN¥680.6M).
Debt to Equity History and Analysis
Debt Level: 300972 has more cash than its total debt.
Reducing Debt: 300972's debt to equity ratio has increased from 64.2% to 105.2% over the past 5 years.
Debt Coverage: 300972's debt is well covered by operating cash flow (164%).
Interest Coverage: 300972's interest payments on its debt are well covered by EBIT (15.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 17:33 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fujian Wanchen Biotechnology Group Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wendan Wang | China International Capital Corporation Limited |
| Chenghui Xiong | Huatai Research |
| Junhao Fan | Huatai Research |